InMed Pharmaceuticals (INM) Consolidated Net Income (2021 - 2025)
Historic Consolidated Net Income for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$2.0 million.
- InMed Pharmaceuticals' Consolidated Net Income rose 2123.48% to -$2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.7 million, marking a year-over-year increase of 306.04%. This contributed to the annual value of -$8.2 million for FY2025, which is 633.94% down from last year.
- InMed Pharmaceuticals' Consolidated Net Income amounted to -$2.0 million in Q4 2025, which was up 2123.48% from -$1.7 million recorded in Q3 2025.
- In the past 5 years, InMed Pharmaceuticals' Consolidated Net Income registered a high of -$336591.0 during Q2 2023, and its lowest value of -$7.9 million during Q2 2022.
- In the last 5 years, InMed Pharmaceuticals' Consolidated Net Income had a median value of -$2.1 million in 2022 and averaged -$2.6 million.
- As far as peak fluctuations go, InMed Pharmaceuticals' Consolidated Net Income surged by 9572.31% in 2023, and later plummeted by 47356.58% in 2024.
- InMed Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$4.3 million in 2021, then skyrocketed by 51.01% to -$2.1 million in 2022, then grew by 29.55% to -$1.5 million in 2023, then plummeted by 74.2% to -$2.6 million in 2024, then grew by 21.23% to -$2.0 million in 2025.
- Its Consolidated Net Income was -$2.0 million in Q4 2025, compared to -$1.7 million in Q3 2025 and -$1.8 million in Q2 2025.